Better health for people, brighter future for the world


Takeda is a leading global biopharmaceutical company based in Japan, guided by the Takeda values of Integrity, Fairness, Honesty and Perseverance. These values live on in our actions, which are taken with the Patient, Trust, Reputation, Business (PTRB) algorithm as the basis and order .

We are in 80 countries, we have 31 plants and 3 research centers around the world, we have about 47,000 employees, and we are a TOP Employer in 38 countries.

Takeda in Portugal is TOP Employer for the third consecutive year in 2022 and focuses its efforts in the areas of Oncology, Gastroenterology, Rare Hematology & Plasma Derived Therapies, Rare Genetic Diseases and Hereditary Angioedema. We also invest in R&D focused on Neurosciences and Vaccines.

Since 2009 in the country, at Takeda we have treated over 1700 patients annually. We have about 50 employees. The company is in the TOP 10 of the national pharmaceutical industry ranking.

Takeda has 40 products in its clinical pipeline, and of these, about 50% have orphan designation. We are leaders in rare diseases and specialty medicine, with the potential to launch 10 new orphan drugs in the next 5-7 years.

Of Takeda’s 240-year history, 80 have been linked to innovation in the field of rare diseases, both in immunology, hematology and gastroenterology, and in metabolic and lysosomal diseases, as well as aspiring to cure cancer with a focus also on certain types of low-prevalence tumors.

The imperatives that guide Takeda are threefold: Patients, People, and Planet.

At Takeda we aim to build a future where all people with diseases have research dedicated to enabling them to have a better future and access to the best innovation that allows them to have a better quality of life. And we know that this is only possible with partnerships and with everyone’s involvement and participation.

At Takeda, we are committed to all projects and partnerships that contribute to finding the best solutions for patients, proposing necessary improvements to the healthcare system and always in collaboration with all stakeholders.